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Objective: To observe the after-effect duration of kidney-nourishing and marrow-replenishing therapy on 
Mediterranean anemia. Methods: To observe the kidney-nourishing and marrow-replenishing therapy on 58 
cases of Mediterranean anemia and the influence of various relative factors on the after-effect duration. 
Results: The after-effect duration on 58 cases varied from 3-6 months, about 4 months on average, and was 
not influenced by sex, clinical types, genetic types, types of Mediterranean anemia and other factors. 
Conclusion: Kidney-nourishing and marrow-replenishing therapy used to treat Mediterranean anemia can 
not only produce good therapeutic effect during treatment but also keep after effect lasting for about 4 
months, indicating that the therapy used to treat Mediterranean anemia has good clinical after effect.  
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Mediterranean anemia is a chronic hemolytic disease 
caused by imbalance of peptide chain because genetic 
mutation or defect of one globin or more inhibits the 
synthesis of its peptide chain. In order to determine 
the after effect of kidney-nourishing and marrow- 
replenishing therapy on Mediterranean anemia, the 
research team observed the after-effect duration of 
the therapy on 58 cases from 1993 to 2004. 
CLINICAL MATERIALS 
Criteria for Diagnosis and Inclusion 
According to the criteria for diagnosing 
Mediterranean anemia in “Criteria for Diagnosis and 
Therapeutic Effect on Hematopathy” edited by 
ZHANG Zhi-nan,1 patients with Į-Mediterranean 
anemia hemoglobin H disease (HbH disease) as well 
as severe or moderate ȕ-Mediterranean anemia with 
no blood transfusion or in take of anti-anemia drug in 
recent half a year. 
Criteria for Exclusion     
1) Patients have immunologic deficiency or other 
primary diseases of the liver, kidney and blood 
system. 2) Patients do not take drugs according to 
instructions or their data are incomplete, thus 
influencing the determination of therapeutic effect.  
General Data 
From October 1993 to June 2004, at No.303 Hospital 
of PLA used as a clinical research base, among 67 out 
of 89 patients coming from Nanning and its 
surrounding area who conformed to the criteria for 
diagnosis and inclusion and were willing to accept 
treatment according to research conditions, 62 
effective cases (with effective rate at 92.5%) were 
observed for the after-effect duration. 58 appraisable 
cases were collected (with the rate of follow-up visits 
at 86.6%). 
Among the 58 patients, 3 cases had HbH disease, 25 
cases had severe ȕ-Mediterranean anemia and 30 
cases had moderate ȕ-Mediterranean anemia. There 
were 38 males and 20 females aged 2.3–31, 12.2±6.8 
on average; 10 people of Han nationality, 45 people 
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of Zhuang nationality, 2 people of Yao nationality 
and 1 person of Miao nationality; 2 people from 
Guangdong and 56 people from Guangxi. 
METHODS 
Therapeutic Method 
Chinese drugs for nourishing the kidney and 
replenishing marrow (capsule and granule for 
replenishing marrow and generating blood) were 
used in the treatment for 2–3 months. During 
observation, patients were asked to have no blood 
transfusion, but keep on taking the drugs. 
Capsule and granule for replenishing marrow and 
generating blood, consisting of Shan Zhu Yu (ቅ㤅㨌
Fructus Corni), He Shou Wu (ԩ佪Р Radix Polygoni 
Multiflori), Shu Di Huang ( ❳ ഄ 咘 Radix 
Rehmanniae Preparata), Huang Qi (咘㡾 Radix 
Astragali) and Bie Jia (努⬆ Carapax Trionycis), are 
provided by the medicament department of 
Guang’anmen Hospital affiliated to China Academy 
of Chinese Medical sciences. Each capsule contains 
0.4 g powder (1 g powder contains 4.25 g crude drug) 
with batch number 970318. A pack of granules 
contains 10 g powder (1 g powder contains 2.368 g 
crude drug) with batch numbers 990920 and 010811. 
4 capsules or a pack of granules is taken each time, 3 
times a day, with the dosage reduced for children. 
Index and Method of Observation 
1) Observations on the after-effect duration: After 
treatment, the effective cases were asked to come 
back to hospital at a fixed time every month for 
reexamination of their blood parameters: hemoglobin 
concentration (Hb), red cell count (RBC) and 
reticulocyte count (Ret). The time from the day of 
withdraw to the day when hemoglobin concentration 
reduces to the level before treatment is defined as the 
time of maintaining therapeutic effect. If Hb is equal 
to or less than the level before treatment, the previous 
time of reexamination is regarded as valid date 
calculated by months. 2) Influence of relevant factors 
on the after-effect duration: Observations were 
carried out on the influence of sex, clinical type, 
genetic type and Mediterranean anemia type on the 
duration of lasting effect for Mediterranean anemia 
patients. 
Criteria for Therapeutic Effect 
In reference to “Criteria for Dagnosis and 
Therapeutic Effect on Hematopathy” edited by 
ZHANG Zhi-nan,1 increase in red cell count and 
reticulocyte count (Hb, RBC, Ret) and increase in 
hemoglobin concentration (Hb) to more than 5 g/L is 
regarded as effective. Increase in reticulocyte count 
(Ret) alone is not regarded as an effective case. 
Statistical Method 
SPSS10.0 software is used. Enumeration data is used 
for frequency statistics, measurement data is 
expressed in ( x ±s). Paired t test, grouped t test and 
variance analysis of single factor are applied 
respectively according to data types. 
RESULTS 
Observations on The Duration of The After-Effect    
Among 58 patients, 23 cases accounting for 39.7% 
had the therapeutic effect lasted for 3 months, 16 
cases accounting for 27.6% for 6 months, 6 cases 
accounting for 10.3% for 2 months, 6 cases 
accounting for 10.3% for 4 months, 5 cases 
accounting for 8.6% for 1 month, 1 case accounting 
for 1.7% for 5 months and 1 case accounting for 
1.7% for 11 months. According to the statistic 
analysis that 79.3% of the 58 patients had the effect 
lasted for 3–6months, 3.8±1.9 months on average.  
As shown in Table 1, the level of hemoglobin 
concentration, red cell count and reticulocyte count 
of all the 58 patients in the after-effect duration 
determined by months was higher than the level 
before treatment (P<0.05 or P<0.01), indicating that 
the after-effect duration still has a tendency to 
increase.
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Influence of Relevant Factors on The After-Effect 
Duration 
1) Influence of sex on the after-effect duration: As 
shown in Table 2, there is no statistical difference 
between males and females in the after-effect 
duration (P>0.05), indicating that after treatment with 
Chinese drugs for nourishing kidney and replenishing 
marrow, the duration of after effect is not influenced 
by sex.
2) Influence of clinical types on the duration of after 
effect: As shown in Table 3, there is no statistical 
difference between severe type and moderate type in 
the after-effect duration (P>0.05), indicating that 
after treatment with Chinese drugs for nourishing 
kidney and replenishing marrow, the duration of after 
effect is not influenced by clinical types.
3) Influence of genetic types on the after-effect 
duration: As shown in Table 4, there is no statistical 
difference among homozygous type, dual heter- 
ozygous type and heterozygous type in the after- 
effect duration (P>0.05), indicating that after 
treatment with Chinese drugs for nourishing kidney 
and replenishing marrow, the after-effect duration is 
not influenced by genetic types.
4) Influence of Mediterranean anemia types on the 
after-effect duration: As shown in Table 5, there is no 
statistical difference between ȕ Mediterranean 
anemia and Į-Mediterranean anemia in the after- 
effect duration (P>0.05), indicating that after 
treatment with Chinese drugs for nourishing kidney 
and replenishing marrow, the after-effect duration is 
not influenced by Mediterranean anemia types.
Table 1. Comparison of blood parameters of 58 patients before treatment 
 and the after-effect duration determined by month ( x fs) 
Time     Hb (g/L) RBC (×1012/L) Ret (%) 
Before treatment 66.78±18.58 3.29±0.87 0.15±0.47 
After-effect duration determined by month 74.88±19.62 **    3.66±0.96 **  0.17±0.41* 
Notes: *P<0.05, **P<0.01 as compared with the datum before treatment. 
Table 2 Comparison of after-effect duration and blood parameters of  
patients with different sex determined month ( x ±s) 
Sex   Cases Duration of after-effect (month) Hb (g/L) RBC (×1012/L) Ret (%) 
Male 38  3.71±1.78 74.50±21.33 3.75±0.91 0.10±0.05 
Female 20  4.05±2.11 75.60±16.36 3.48±1.05 0.30±0.69 
Table 3 Comparison of time of maintaining therapeutic effect and blood parameters  
of patients with different clinical types determined by month ( x ±s) 
Clinical types Cases Duration of after-effect (month) Hb (g/L) RBC (×1012/L) Ret (%) 
Severe 25 3.76±1.56 59.04±15.19 3.20±0.88 0.12±0.07
Moderate 33 3.88±2.13 86.88±12.97*  4.00±0.88* 0.21±0.54 
Notes: *P<0.01 as compared with the datum in severe type. 
Table 4 Comparison of the after-effect duration and blood parameters of patients with different genetic types 
determined by month ( x ±s) 
Genetic types Cases Duration of after-effect (month) Hb (g/L) RBC (×1012/L) Ret (%) 
Homozygous 10 3.70±1.83 64.50±28.82 2.99±1.07 0.13±0.13 
Dual heterozygous 42 3.83±1.54 75.98±17.33 3.77±0.94 0.12±0.07 
Heterozygous 6 4.00±3.90 84.50±9.65 3.93±0.31  0.60±1.27*
Notes: *P<0.05 as compared with the datum in dual heterozygous type.
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Table 5 Comparison of after-effect duration and blood parameters of patients 
 with different Mediterranean anemia types determined by month ( x ±s) 
Mediterranean Anemia types Cases Duration of after-effect (month) Hb (g/L) RBC (×1012/L) Ret (%) 
ȕ-Mediterranean anemia 55 3.80±1.59  74.38±20.02 3.63±0.98 0.12±0.08
Į-Mediterranean anemia 3 4.33±5.77 84.00±3.61 4.04±0.45 1.13±1.80
DISCUSSION 
Clinical symptoms and signs of patients with 
Mediterranean anemia are mainly characterized by 
sallow complexion, pale nails, dizziness, palpitation, 
short breath, fatigue, lassitude in loin and knees, 
delayed growth and development. Professor WU 
Zhi-kui believes that its pathogenesis mainly lies in 
deficiency of the kidney essence and deficiency of 
essence and blood. In TCM, it is held that the kidney 
produces marrow and marrow generates blood, and 
essence and blood share the same source. According 
to TCM theory, Mediterranean anemia should be 
treated with the method for nourishing the kidney and 
replenishing marrow. Therefore, a representative 
recipe of Chinese drugs for nourishing the kidney and 
replenishing marrow (capsule and granule for 
replenishing marrow and generating blood) has been 
prescribed. The recipe consisting of Shan Zhu Yu (ቅ
㤅㨌 Fructus Corni), He Shou Wu (ԩ佪Р Radix 
Polygoni Multiflori), Shu Di Huang (❳ഄ咘 Radix 
Rehmanniae Preparata) and other ingredients can 
reinforce the kidney, replenish qi and nourish blood 
with the aim at tonifying kidney-yin and marrow to 
strengthen blood-generating source.2 Professor WU 
Zhi-kui and others used 11 batches of capsules and 
granules for nourishing the kidney and replenishing 
marrow to treat 156 cases of ȕ-Mediterranean anemia 
in an area of Guangxi with high incidence of 
Mediterranean anemia from 1989 to 2005. The 
treatment achieved affirmative therapeutic effect 
which can be repeated with the total effective rate at 
92.9%.3      
In order to further determine the after effect of 
kidney-nourishing and marrow-replenishing therapy 
on Mediterranean anemia, the research team has 
observed the after-effect duration on some patients 
treated with kidney-nourishing and marrow- 
replenishing therapy. Through statistics, 58 patients 
generally had the after-effect duration for 3-6 months, 
about 4 months on average. Further analysis has 
shown that the after-effect duration is not influenced 
by sex, clinical types, genetic types and 
Mediterranean anemia types. Clinical data have 
shown that the average life-span of mature red cells is 
120 days in healthy people and 30–40 days in 
Mediterranean anemia patients. Owing to greatly 
shortened life-span of red cells, Mediterranean 
anemia patients are clinically characterized by 
hemolysis, anemia and other pathological changes. 4 
months after drug withdraw, Mediterranean anemia 
patients treated with kidney-nourishing and marrow-
replenishing therapy can still keep hemoglobin 
concentration and red cell count higher than the level 
before treatment, indicating that kidney-nourishing 
and marrow-replenishing therapy can effectively 
influence hemolysis and anemia of Mediterranean 
anemia patients. Yet, concrete pathogenesis and 
functions remain to be further studied. 
In general, the following conclusion can be drawn 
from the observations during follow-up visits. The 
treatment of Mediterranean anemia with kidney- 
nourishing and marrow-replenishing therapy can not 
only achieve good therapeutic effect during treatment 
but also let the therapeutic effect last for about 4 
months after drug withdraw, indicating that kidney-
nourishing and marrow-replenishing therapy has 
good after effect on Mediterranean anemia. 
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